ATENOLOL AND CHLORTHALIDONE TABLETS USP

/ATENOLOL AND CHLORTHALIDONE TABLETS USP
ATENOLOL AND CHLORTHALIDONE TABLETS USP2018-09-06T09:12:40+00:00

Prescription Drug Name:

ATENOLOL AND CHLORTHALIDONE TABLETS USP

ID:

86da35ec-fbfa-4474-bf4b-a58d9c737a19

Code:

34391-3

DESCRIPTION


id: 87ed8ba0-7e89-4642-a82f-ccd3529b9700
displayName: DESCRIPTION SECTION
FDA Article Code: 34089-3

Atenolol and chlorthalidone is for the treatment of hypertension. It combines the antihypertensive activity of two agents: a beta1-selective (cardioselective) hydrophilic blocking agent (atenolol) and a monosulfonamyl diuretic (chlorthalidone). Atenolol is Benzeneacetamide, 4-[2′-hydroxy-3′-[(1-methylethyl) amino] propoxy]-. The molecular and structural formulas are:

C14H22N2O3

Atenolol (free base) is a relatively polar hydrophilic compound with a water solubility of 26.5 mg/mL at 37°C. It is freely soluble in 1N HCl (300 mg/mL at 25°C) and less soluble in chloroform (3 mg/mL at 25°C). Chlorthalidone is 2-Chloro-5-(1-hydroxy-3-oxo-1-isoindolinyl) benzene sulfonamide. The molecular and structural formulas are:

C14H11CIN2O4S

Chlorthalidone has a water solubility of 12 mg/100 mL at 20°C. Atenolol and chlorthalidone tablets for oral administration are available as:

Atenolol 50 mg
Chlorthalidone 25 mg
or
Atenolol 100 mg
Chlorthalidone 25 mg
Inactive ingredients: magnesium stearate, microcrystalline cellulose, povidone, and sodium starch glycolate.

INDICATIONS AND USAGE


id: 44b8b980-e9fa-4bd0-b2c9-b001d2dc2e2d
displayName: INDICATIONS & USAGE SECTION
FDA Article Code: 34067-9

Atenolol and chlorthalidone tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including atenolol and chlorthalidone. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. This fixed dose combination drug is not indicated for initial therapy of hypertension. If the fixed dose combination represents the dose appropriate to the individual patient’s needs, it may be more convenient than the separate components.

CONTRAINDICATIONS


id: a65ec389-492d-44a4-9913-1f76790d89ff
displayName: CONTRAINDICATIONS SECTION
FDA Article Code: 34070-3

Atenolol and chlorthalidone tablets are contraindicated in patients with: sinus bradycardia; heart block greater than first degree; cardiogenic shock; overt cardiac failure (see WARNINGS ); anuria; hypersensitivity to this product or to sulfonamide-derived drugs.

ADVERSE REACTIONS


id: b3be1592-6207-48fd-8331-baa19f0eabac
displayName: ADVERSE REACTIONS SECTION
FDA Article Code: 34084-4

Atenolol and chlorthalidone is usually well tolerated in properly selected patients. Most adverse effects have been mild and transient. The adverse effects observed for atenolol and chlorthalidone are essentially the same as those seen with the individual components.

POTENTIAL ADVERSE EFFECTS


id: 814ee3bb-182b-4b5f-94ac-d6c869b10e71
displayName: SPL UNCLASSIFIED SECTION
FDA Article Code: 42229-5

In addition, a variety of adverse effects not observed in clinical trials with atenolol but reported with other beta-adrenergic blocking agents should be considered potential adverse effects of atenolol. Nervous System: Reversible mental depression progressing to catatonia; an acute reversible syndrome characterized by disorientation for time and place, short-term memory loss, emotional lability, slightly clouded sensorium, decreased performance on neuropsychometrics; Cardiovascular: Intensification of AV block (see CONTRAINDICATIONS ); Gastrointestinal: Mesenteric arterial thrombosis, ischemic colitis; Hematologic: Agranulocytosis; Allergic: Erythematous rash, fever combined with aching and sore throat, laryngospasm and respiratory distress.

OVERDOSAGE


id: 12224178-5427-43d9-8f33-d72429a2ad6f
displayName: OVERDOSAGE SECTION
FDA Article Code: 34088-5

No specific information is available with regard to overdosage and atenolol and chlorthalidone in humans. Treatment should be symptomatic and supportive and directed to the removal of any unabsorbed drug by induced emesis, or administration of activated charcoal. Atenolol can be removed from the general circulation by hemodialysis. Further consideration should be given to dehydration, electrolyte imbalance and hypotension by established procedures.

DOSAGE AND ADMINISTRATION


id: c1a2cadf-af39-4baa-8c39-5e65aca21a2d
displayName: DOSAGE & ADMINISTRATION SECTION
FDA Article Code: 34068-7

DOSAGE MUST BE INDIVIDUALIZED. (See INDICATIONS AND USAGE.) Chlorthalidone is usually given at a dose of 25 mg daily; the usual initial dose of atenolol is 50 mg daily. Therefore, the initial dose should be one atenolol and chlorthalidone tablet 50 mg/25 mg given once a day. If an optimal response is not achieved, the dosage should be increased to one atenolol and chlorthalidone tablet 100 mg/25 mg given once a day. When necessary, another antihypertensive agent may be added gradually beginning with 50 percent of the usual recommended starting dose to avoid an excessive fall in blood pressure. Since atenolol is excreted via the kidneys, dosage should be adjusted in cases of severe impairment of renal function. No significant accumulation of atenolol occurs until creatinine clearance falls below 35 mL/min/1.73m2 (normal range is 100–150 mL/min/1.73m2); therefore, the following maximum dosages are recommended for patients with renal impairment.

Creatinine Clearance
(mL/min/1.73m2)
Atenolol Elimination
Half-life (hrs)
Maximum Dosage
15–35 16–27 50 mg daily
<15 >27 50 mg every other day

HOW SUPPLIED


id: 2c95a305-c0f6-4911-a62a-50d461c723bb
displayName: HOW SUPPLIED SECTION
FDA Article Code: 34069-5

Atenolol and chlorthalidone tablets, USP are available in two strengths: Atenolol 50 mg and chlorthalidone 25 mg round, white, scored, debossed MP 153

Bottles of 50 NDC 53489-531-02
Bottles of 100 NDC 53489-531-01
Bottles of 250 NDC 53489-531-03
Bottles of 500 NDC 53489-531-05
Bottles of 1000 NDC 53489-531-10
Atenolol 100 mg and chlorthalidone 25 mg round, white, unscored, debossed MP 152
Bottles of 50 NDC 53489-532-02
Bottles of 100 NDC 53489-532-01
Bottles of 250 NDC 53489-532-03
Bottles of 500 NDC 53489-532-05
Bottles of 1000 NDC 53489-532-10

PRINCIPAL DISPLAY PANEL – 50 mg/25 mg Bottle


id: d023a834-c9aa-4a91-b2a8-1a130d7eb9ae
displayName: PACKAGE LABEL.PRINCIPAL DISPLAY PANEL
FDA Article Code: 51945-4

MP NDC 53489-531-01 ATENOLOL AND
CHLORTHALIDONE TABLETS USP
50 mg/25 mg 100 TABLETS
Rx only
MUTUAL PHARMACEUTICAL CO., INC.

PHILADELPHIA, PA 19124 USA

PRINCIPAL DISPLAY PANEL – 100 mg/25 mg Bottle


id: 502a2c96-6908-42ec-85fc-8b6375da1199
displayName: PACKAGE LABEL.PRINCIPAL DISPLAY PANEL
FDA Article Code: 51945-4

MP NDC 53489-532-01 ATENOLOL AND
CHLORTHALIDONE TABLETS USP
100 mg/25 mg 100 TABLETS
Rx only
MUTUAL PHARMACEUTICAL CO., INC.

PHILADELPHIA, PA 19124 USA